Full Text
Abstract
Introduction. Cerebrovascular diseases (CVD) present a major concern for modern healthcare due to high mortality and dis- ability rates. Hemorheological and hemocoagulation disturbances play one from main etiopathogenetic aspects in the devel- opment and progression of CVD.
Aim: to estimate some hemorheological and hemostasis parameters together with biomarker profile in patients with isch- emic CVD.
Materials and methods. The study comprised 454 patients (mean age — 66.3 ± 8.1 years; men — 56%) with > 50% internal ca- rotid artery (ICA) stenosis. Along with a thorough clinical and neurological examination, the patients underwent carotid ultra- sound, brain MRI, and blood analyses, including hemorheological and hemostasis parameters as well as biomarkers of CVD.
Results. It has been demonstrated that the presence of atherosclerotic lesions of the ICA is associated with profound chang- es in hemorheology and hemostasis. The biomarker profile allowed us to develop a risk scale of CVD progression — with the highest score corresponding to the greatest risk.
Conclusion. The found blood alterations represent the complexity of CVD pathogenesis. The studied biomarkers may be used as a predicting tool for evaluating the risk of CVD progression.
REFERENCES
1. Feigin V. L., Forouzanfar M. H., Krishnamurthi R. et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study. Lancet. 2014; 383 (9913): 245– 54. PMID: 24449944.
2. Biomarkers and surrogate endpoints: Preferred definitions and con- ceptual framework. Clin Pharmacol Ther. 2001; 69: 89–95. DOI: 10.1067/mcp. 2001.113989. PMID: 11240971.
3. Roitman E. V. Bioreology. Clinical hemorheology. Basic concepts, parameters, equipment (lecture). [Bioreologiya. Klinicheskaya gemoreologiya. Osnovnye ponyatiya, pokazateli, oborudovanie (lekciya)]. Klinicheskaya laboratornaya diagnostika. 2001; 5: 25–32 (in Russ).
4. Muraviev A. V., Roitman E. V., Levin V. N. et al. Changes of blood rheological properties in individuals with cerebral atherosclero- sis under drug therapy with pentoxifylline (trental). [Izmenenie reologicheskih svojstv krovi u lic s cerebral’nym aterosklerozom v usloviyah lekarstvennoj terapii pentoksifillinom (trentalom)]. Tromboz, gemostaz i reologiya. 2010; 2: 28–33 (in Russ).
5. Tanashyan M. M., Domashenko M. A., Raskurazhev A. A. Aspi- rin resistance: Clinical and molecular genetic evaluation tech- niques. Human Physiology. 2017; 43 (8): 904–909. DOI: 10.1134/ S0362119717080126.
6. Witkowski Yu. A., Kuznik B. I., Govorin A. V. et al. Hemostasis, leu- kocyte-platelet relationships, acute phase inflammation proteins and cytokines in patients with various forms of coronary heart dis- ease. [Sistema gemostaza, lejkocitarno-trombocitarnye vzaimoot- nosheniya, belki ostroj fazy vospaleniya i citokiny u bol’nyh s razli- chnymi formami ishemicheskoj bolezni serdca]. Tromboz, gemo- staz i reologiya. 2009; 1: 49–63 (in Russ).
7. Tanashyan M. M., Suslina Z. A., Ionova V. G. et al. Hemorheolo- gy and hemostasis in patients with ischemic stroke with different lesion degrees of the main head arteries. [Gemoreologiya i gemo- staz u bol’nyh s ishemicheskim insul’tom pri razlichnoj stepeni porazheniya magistral’nyh arterij golovy]. Nevrologicheskij zhur- nal. 2001; 6 (6): 17–21 (in Russ).
8. Libby P., Ridker P. M., Hansson G. K. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from patho- physiology to practice. J Am Coll Cardiol. 2009; 54 (23): 2129–38. DOI: 10.1016/j. jacc. 2009.09.009. PMID: 19942084.
9. Pandolfi A., Cetrullo D., Polishuck R. et al. Plasminogen activa- tor inhibitor type 1 is increased in the arterial wall of type II dia- betic subjects. Arterioscler Thromb Vasc Biol. 2001; 21 (8): 1378– 82. PMID: 11498469.
10. Orlov S. V., Domashenko M. A., Kostyreva M. V. et al. Hemorhe- ology and hemostasis in patients with ischemic strokes and met- abolic syndrome. [Gemoreologiya i gemostaz u bol’nyh ishemi- cheskimi insul’tami na fone metabolicheskogo sindroma]. Klin- icheskaya medicina. 2007; 1 (85): 40–3 (in Russ).
11. Ballantyne C. M., Hoogeveen R. C., Bang H. et al. Lipoprotein- associated phospholipase A2, high-sensitivity C-reactive pro- tein, and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Arch Intern Med. 2005; 165: 2479–84. DOI: 10.1161/01. CIR.0000116763.91992. F1. PMID: 14757686.
12. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arte- rial thrombosis. Circ Res. 2001; 88: 756–62. PMID: 11325866.
13. Muraviev A. V., Roitman E. V., Tikhomirova I. A. et al. Deform- ability of erythrocytes: the basic mechanisms of urgent adaptation. [Deformiruemost’ eritrocitov: osnovnye mekhanizmy srochnoj adaptacii]. Tromboz, gemostaz i reologiya. 2013; 3: 4–17 (in Russ).
14. BouchJ.L.,HansenH.,FeenerE.P.Natriureticfactorsandnitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol. 1998; 18: 1771–9. PMID: 9812917.
15. Ouchi N., Kihara S., Arita Y. et al. Adiponectin, an adipocyte- derived plasma protein, inhibits endothelial NF-kappaB signal- ing through a cAMP-dependent pathway. Circulation. 2000; 102: 1296–301. PMID: 10982546.
16. Arita Y., Kihara S., Ouchi N. et al. Adipocyte-derived plasma pro- tein adiponectin acts as a platelet-derived growth factor-BB-bind- ing protein and regulates growth factor-induced common post- receptor signal in vascular smooth muscle cell. Circulation. 2002; 105: 2893–98. PMID: 12070119.
17. Ouchi N., Kihara S., Arita Y. et al. Adipocyte-derived plasma pro- tein, adiponectin, suppresses lipid accumulation and class A scav- enger receptor expression in human monocyte-derived macro- phages. Circulation. 2001; 103: 1057–63.
18. Okamoto Y., Arita Y., Nishida M. et al. An adipocyte-derived plas- ma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000; 32: 47–50. PMID: 10741683. DOI: 10.1055/ s-2007–978586.
19. Okamoto Y., Kihara S., Ouchi N. et al. Adiponectin reduces ath- erosclerosis in apolipoprotein E-deficient mice. Circulation. 2002; 106: 2767–70. PMID: 12451000.
20. Kumada M., Kihara S., Sumitsuji S. et al. Association of hypoad- iponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003; 23: 85–9. PMID: 12524229.